Under One Roof: Identification, Evaluation, and Treatment of Chronic Hepatitis C in Addiction Care

Overview

Journal Addict Sci Clin Pract

Publisher Biomed Central

Specialty Psychiatry

Date 2018 Apr 26

PMID 29690936

Citations 11

Authors

Stephen A Martin

Jordon Bosse

Amanda Wilson

Phyllis Losikoff

Lisa Chiodo

Affiliations

Soon will be listed here.

Abstract

For over a decade, the vast majority of new hepatitis C virus (HCV) infections have been among young people who inject drugs (PWID). Well-characterized gaps in chronic HCV diagnosis, evaluation, and treatment have resulted in fewer than 5% of PWID receiving HCV treatment. While interferon-based treatment may have intentionally been foregone during part of this time in anticipation of improved oral therapies, the overall pattern points to deficiencies and treatment exclusions in the health care system. Treatment for HCV with all-oral, highly effective direct-acting antiviral medication for 12 weeks or less is now the standard of care, putting renewed focus on effective delivery of care. We describe here both the need for and process of chronic HCV care under the roof of addiction medicine.

Citing Articles

Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder.

Haque L, Leggio L Hepatology. 2024; 80(6):1408-1423.

PMID: 38935926 PMC: 11841743. DOI: 10.1097/HEP.0000000000000996.

Association of psychosocial risk factors and liver transplant evaluation outcomes in metabolic dysfunction-associated steatotic liver disease.

Wang R, Lee J, Mirda D, Hao J, Goebel A, Deutsch-Link S Liver Transpl. 2024; 30(12):1226-1237.

PMID: 38869989 PMC: 11560602. DOI: 10.1097/LVT.0000000000000421.

Integrated hepatitis C treatment is associated with improved retention and success in outpatient treatment for opioid use disorder at a private clinic.

Losikoff P, Bosse J, Martin S, Wilson A, Chiodo L Front Psychiatry. 2022; 13:932306.

PMID: 36186876 PMC: 9515307. DOI: 10.3389/fpsyt.2022.932306.

Hepatitis C models of care: approaches to elimination.

Biondi M, Feld J Can Liver J. 2022; 3(2):165-176.

PMID: 35991853 PMC: 9202783. DOI: 10.3138/canlivj.2019-0002.

Primary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting.

Haque L, Butner J, Shi J, Henry S, Deng Y, Ciarleglio M J Addict Med. 2021; 16(3):333-339.

PMID: 34483278 PMC: 9033626. DOI: 10.1097/ADM.0000000000000910.

References

Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D . Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011; 364(23):2199-207. PMC: 3820419. DOI: 10.1056/NEJMoa1009370. View

Ghany M, Morgan T . Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2019; 71(2):686-721. PMC: 9710295. DOI: 10.1002/hep.31060. View

Razavi H, Elkhoury A, Elbasha E, Estes C, Pasini K, Poynard T . Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013; 57(6):2164-70. PMC: 3763475. DOI: 10.1002/hep.26218. View

Grassi A, Ballardini G . Hepatitis C in injection drug users: It is time to treat. World J Gastroenterol. 2017; 23(20):3569-3571. PMC: 5449413. DOI: 10.3748/wjg.v23.i20.3569. View

Holmberg S, Spradling P, Moorman A, Denniston M . Hepatitis C in the United States. N Engl J Med. 2013; 368(20):1859-61. PMC: 5672915. DOI: 10.1056/NEJMp1302973. View

Schitz A, Moser S, Marchart K, Haltmayer H, Gschwantler M . Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy. Am J Gastroenterol. 2016; 111(6):903-5. DOI: 10.1038/ajg.2016.119. View

Laraque F, Varma J . A Public Health Approach to Hepatitis C in an Urban Setting. Am J Public Health. 2017; 107(6):922-926. PMC: 5425859. DOI: 10.2105/AJPH.2017.303718. View

Krans E, Zickmund S, Rustgi V, Park S, Dunn S, Schwarz E . Screening and evaluation of hepatitis C virus infection in pregnant women on opioid maintenance therapy: A retrospective cohort study. Subst Abus. 2015; 37(1):88-95. PMC: 4827149. DOI: 10.1080/08897077.2015.1118720. View

Alavi M, Grebely J, Micallef M, Dunlop A, Balcomb A, Day C . Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. Clin Infect Dis. 2013; 57 Suppl 2:S62-9. DOI: 10.1093/cid/cit305. View

10.

Butner J, Gupta N, Fabian C, Henry S, Shi J, Tetrault J . Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. J Subst Abuse Treat. 2017; 75:49-53. DOI: 10.1016/j.jsat.2016.12.014. View

11.

Clark P, Muir A . Overcoming barriers to care for hepatitis C. N Engl J Med. 2012; 366(26):2436-8. DOI: 10.1056/NEJMp1202608. View

12.

Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A . Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013; 57 Suppl 2:S129-37. DOI: 10.1093/cid/cit302. View

13.

. Hepatitis Awareness Month and Testing Day - May 2019. MMWR Morb Mortal Wkly Rep. 2019; 68(18):413. PMC: 6542190. DOI: 10.15585/mmwr.mm6818a1. View

14.

Carey K, Huang W, Linas B, Tsui J . Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders. J Subst Abuse Treat. 2016; 66:54-9. PMC: 5097249. DOI: 10.1016/j.jsat.2016.01.009. View

15.

Stopka T, Goulart M, Meyers D, Hutcheson M, Barton K, Onofrey S . Identifying and characterizing hepatitis C virus hotspots in Massachusetts: a spatial epidemiological approach. BMC Infect Dis. 2017; 17(1):294. PMC: 5399408. DOI: 10.1186/s12879-017-2400-2. View

16.

Martin N, Vickerman P, Grebely J, Hellard M, Hutchinson S, Lima V . Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013; 58(5):1598-609. PMC: 3933734. DOI: 10.1002/hep.26431. View

17.

Zeremski M, Zibbell J, Martinez A, Kritz S, Smith B, Talal A . Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol. 2013; 19(44):7846-51. PMC: 3848132. DOI: 10.3748/wjg.v19.i44.7846. View

18.

Yehia B, Schranz A, Umscheid C, Lo Re 3rd V . The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014; 9(7):e101554. PMC: 4079454. DOI: 10.1371/journal.pone.0101554. View